Optimization of Treatment and Management of Schizophrenia in Europe

Rene Kahn479 enrolled

Overview

The purpose of the study is optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development.

Despite nearly fifty years of pharmacological and psychosocial research, the overall prognosis of schizophrenia has improved only marginally. While the efficacy of most antipsychotic medication is generally uncontested, their overall functional impact has been modest. In order to improve this unsatisfactory result, this study aims to optimize current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study comprises a medication intervention component, a psychosocial intervention component, a biological predictor component and an MRI component. MRI assessments are performed at baseline, and used to determine whether potential organic causes for psychotic symptoms are present, and to test prospective value of these assessments for subsequent treatment response. MRI assessments of healthy volunteers will be included to test for deviations in patients' assessments; these volunteers will not participate in any other protocol procedure. The medication intervention component comprises a first 4-week phase of amisulpride treatment. Non-responders will subsequently be randomised to a 6-week double blind phase on either amisulpride or olanzapine. Patients who classify as non-responders at the end of this phase, a 12-week open label treatment with clozapine is initiated. Patients who classify as a responder in phase I, II or III, are drop outs or who are non-responders at the end of phase III flow to the psychosocial intervention component of the study. During this part, several interventions are tested, aimed to increase treatment compliance and keep patients on the medication to which they've responded well. Through the biological predictor component, it is determined whether glutamatergic markers predict response to first and second line treatments, and if an empirical combination of pharmacogenetic, proteomics- and metabolomic markers can provide clinical valuable predictive value.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

479

Conditions

Schizophrenia Schizophreniform Disorder Schizoaffective Disorder

Interventions

Amisulpride open labelDRUG

4-week open label amisulpride treatment

6-week amisulpride double blind treatmentDRUG

6-week amisulpride double blind treatment

6-week olanzapine double blind treatmentDRUG

6-week olanzapine double blind treatment

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosis of schizophrenia as defined by DSM-IV-R as determined by the M.I.N.I.plus 2. Age 18 or older. 3. The first psychosis occurred at least one year and no more than 7 years ago.\* 4. If patients are using an antipsychotic drug, a medication switch is currently under consideration. 5. Capable of providing written informed consent. Exclusion Criteria: 1. Intolerance / hypersensitivity to one of the drugs (including active substances, metabolites and excipients) in this study including oral risperidone, paliperidone and aripiprazole and/or hypersensitivity to risperidone. 2. Pregnancy or lactation. 3. Patients who are currently using clozapine. 4. Patients who do not fully comprehend the purpose or are not competent to make a rational decision whether or not to participate. 5. Patients with a documented history of non-response and/or intolerance to any of the study medications and/or a documented history of non-response to a treatment with one of the study drugs of at least 6 weeks within the registered dose range. 6. Forensic patients. 7. Patients who have been treated with an investigational drug within 30 days prior to screening. 8. Simultaneous participation in another intervention study (neither medication or psychosocial intervention).

Locations (26)

Outcomes

Primary Outcomes

PANSS

Study consists of multiple components, each with their own objectives. For this (medication) component: number of patients in remission, based on PANSS scores (criteria of Andreasen et al.; 2005) after 4 weeks open label amisulpride, after 6 weeks double blind amisulpride or olanzapine and after 12 weeks of open label clozapine.

Time frame: Jan 2016

Sellwood rating scale

Psychosocial intervention component, objective A: drug adherence rates as a function of (standardized self report and) Sellwood rating scales after 12 and 52 weeks.

Time frame: Jan 2016

Biological profile

Biological predictors component, objective A: drug response (remission vs non-remission) as a function of biological profile, after 4 weeks, 10 weeks and 22 weeks (after each medication phase).

Time frame: jan 2016

MRS measures

Biological predictors component, objective B: using MRS scans, differences between responders and non-responders in regional glutamate levels a) at baseline and b) between baseline and after one month of treatment with amisulpiride.

Time frame: jan 2016

SOFAS global functioning

Psychosocial intervention component, objective B: drug adherence rates as a function of standardized global functioning (SOFAS score after 1 year) following psychosocial intervention vs treatment as usual.

Time frame: jan 2016

MRI assessments

MRI component objective: the percentage of first episode patients that show radiological abnormalities suggestive of neurological disorders which may explain the occurrence of psychotic symptoms - measurement at baseline only.

Time frame: jan 2016

Secondary Outcomes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Melbourne Neuropsychiatry Centre

Melbourne, Australia

Department of Biological Psychiatry, Innsbruck University Clinics

Innsbruck, Austria

Katholieke Universiteit Leuven (KU Leuven)

Leuven, Belgium

University Specialised Hospital for Active Treatment in Neurology and Psychiatry "St. Naum"

Sofia, Bulgaria

Psychiatrické centrum Praha

Prague, Ustavni 91, Czechia

Psychiatrická klinika LF UK, Fakultní nemocnice

Hradec Králové, Czechia

Center for Neuropsychiatric Research

Glostrup Municipality, Denmark

Institut National de la Santé et de la Reserche Médicale (INSERM)

Créteil, France

Martin-Luther-University (MLU) of Halle-Wittenberg

Halle, Germany

Deprtment of Psychiatry, University of Heidelberg

Mannheim, Germany

...and 16 more locations

All cause treatment discontinuation

The different components of the study have their own secondary objectives: Medication component has multiple secondary objectives, most important one is all-cause treatment discontinuation after 4 weeks, 10 weeks and 22 weeks. Number and reason for premature discontinuations (treatment discontinuation) of the amisulpride and the olanzapine group will be compared (after 10 weeks).

Time frame: jan 2016

All cause discontinuation

Psychosocial intervention component has multiple secondary objectives, most important one is all-cause treatment discontinuation between treatment groups after 12 and 52 weeks.

Time frame: jan 2016

Biological markers

Biological predictors component has multiple secondary objectives, most important one is the ability of biological markers to predict response to antipsychotic and treatment tolerability in schizophrenia, after 4, 10 and 22 weeks.

Time frame: jan 2016

MRI assessments

The ability of MRI to predict response to antipsychotic treatment in schizophrenia, after 4, 10 and 22 weeks.

Time frame: jan 2016